Our new website is coming soon, give it a try now and let us have your feedback. Take me to the Beta



Register
Login:
Share:
Email Facebook Twitter


TSX Lithium explorer International Lithium Corp prepares to drill at Raleigh Lake
Exclusive: Hardman & Co Investor Forum - Severn Trent, Calculus Capital, Volta Finance, Residential




Share Price Information for Angle (AGL)


Share Price: 60.00Bid: 59.00Ask: 61.00Change: 1.50 (+2.56%)Riser - Angle
Spread: 2.00Spread as %: 3.39%Open: 58.50High: 60.00Low: 58.50Yesterday’s Close: 58.50

Angle Plc Ord 10P

Angle is listed in the FTSE AIM All-Share
Angle is part of the Support sector






Share Price SpacerPrice
60.00
Share Price SpacerBid
59.00
Share Price SpacerAsk
61.00
Share Price SpacerChange
2.56%1.50
Share Price SpacerVolume
560,677
Share Price SpacerOpen
58.50
Share Price SpacerHigh
60.00
Share Price SpacerLow
58.50
Share Price SpacerClose
58.50
Share Price SpacerCurrency
GBX


Currency Issue Country Shares in Issue Market Capitalisation Market Size
GBX GB 143.49m £86.09m 3,000

52 Week High 79.00 52 Week High Date 31-MAY-2019
52 Week Low 38.00 52 Week Low Date 18-DEC-2018

# Trades Vol. Sold Vol. Bought PE Ratio Earnings Dividend Yield
36 45,930 118,384 -7.585 -7.91 0.00 0.00




Date
Time
Trade Prc
Volume
Buy/Sell
Bid
Ask
Value
 

18-Jun-19
13:08:26
58.76
209,438
Sell* 
59.00
61.00
123.07k
Trade Type:
Ordinary
Delayed publication

18-Jun-19
17:08:24
60.00
52,000
 
59.00
61.00
31.20k
Trade Type:
Ordinary

18-Jun-19
16:29:21
60.37
1,240
Buy* 
59.00
61.00
748.59
Trade Type:
Ordinary




View more Angle trades >>

Directors Deals for Angle (AGL)
Trade DateActionNotifierPriceCurrencyAmountHolding
26-Oct-16Buy
Trade Notifier Information for Angle
Andrew D Newland held the position of CEO at Angle at the time of this trade.
 Andrew D Newland
57GBX1,350,0007054686
30-Apr-16Notification of Holding
Trade Notifier Information for Angle
Ian F Griffiths held the position of Finance Director at Angle at the time of this trade.
 Ian F Griffiths
00559546
30-Apr-16Notification of Holding
Trade Notifier Information for Angle
Garth Selvey held the position of Chairman at Angle at the time of this trade.
 Garth Selvey
0020000
View more Angle directors dealings >>


Bermudashorts
Posts: 10,045
Opinion:No Opinion
Price:58.50
AGL
Mon 14:45
Interesting to note in light of AN's comments re. the use of Parsortix in clinical trials, that a new research paper has been published today by University Medical Center Hamburg-Eppendorf, Germany. The paper investigates the use of Parsortix for the analysis of PD-L1 expression on CTC's.

For any who may not be aware, immunotherapy and specifically checkpoint inhibitors have transformed cancer treatment over recent years. PD-L1 is a protein expressed on the surface of tumour cells and signals to PD-1 on the surface of a T cell telling it not to attack. In effect, it's a mechanism that allows the tumour to hide from the immune system. PD-1 checkpoint inhibitors such as Keytruda (Merck) and Opdivo (BMS) block the pathway and unmask the tumour thereby allowing the immune system to attack. These drugs now have multi billion $ annual sales.

The problem is that only around 30% of patients respond to checkpoint inhibitors in lung cancer and it's thought that responses increase with PD-L1 expression. Clearly with lung cancer, it's impossible to continually monitor PD-L1 expression via tissue biopsy and so it's easy to see how CTCs may be of interest in clinical trials.

You can download the full paper from this link:-

https://www.mdpi.com/2072-6694/11/6/835
seeingtom
Posts: 281
Opinion:No Opinion
Price:58.50
RE: Nice article in the Telegraph
Mon 14:40
With respect to clinical trials, AGL have previously explained that FDA approval is not necessary for Parsortix to be used in clinical trials. That here is no regulatory restriction or problem with using Parsortix now in clinical trials. They say the problem comes with willingness of big pharma decision makers to stick their necks out to bring in use of Parsortix. Many of these decision makers are very conservative due to the way big pharma is run. Most want to use the same methods as everyone else so if anything goes wrong, they can just tell their management that it wasn't their fault because they did the standard thing. Safety in crowds. FDA approval potentially unlocks this because in the unlikely event of anything going wrong, the pharma decision makers can say "oh well, the FDA were happy with it so it isn't my fault". That said, we are told that AGL are already in discussion with Big Pharma. This may big pharma lining up Parsortix usage ready to go as soon as FDA clearance drops. It could be a minority of decision makers who are willing to introduce Parsortix now. My guess is both discussions are happening. And we know Parsortix is already being used by pharma in early stage trials and small scale.
Worth keeping in mind that Parsortix usage in just one single full scale trial could be worth £millions a year in revenue to AGL.
scotlouie
Posts: 4,232
Opinion:No Opinion
Price:58.50
RE: Nice article in the Telegraph
Mon 10:21
Although id love to see that but i just cant see it happening. The big pharmas wont want to take the risk of buying/partnering until FDA approval is given then they can market product. Until then i would guess there might be a few players eying up AGL and maybe already in discussions behind closed doors. Who knows! But until FDA is given i think all of these potential buy outs will be waiting and let AGL do all the leg work and prove parsortix can be a global product/service (in the eyes on fda approval i mean)

Its good to see a little bounce today :)
Morgank
Posts: 471
Opinion:No Opinion
Price:58.00
RE: Nice article in the Telegraph
Mon 08:53
Good find, still think Angle could be taken out before FDA approval , they are delivering on what they set out to do
TallPaulNY
Posts: 731
Opinion:No Opinion
Price:55.60
Nice article in the Telegraph
Mon 07:09
View more share chat for Angle (AGL) >>




Angle Plc Ord 10P home pageWebsite: Angle Plc Ord 10P
Website Description: ANGLEplc.com



Share Price, Share Chat, Stock Market news at lse.co.uk
FREE Member Services
- Setup a personalised Watchlist and Virtual Portfolio.
- Gain access to LIVE real-time Regulatory News (RNS).
- View more Trades, Directors' Deals, and Broker Ratings.
Share Price, Share Chat, Stock Market news at lse.co.uk









Home  |  Contact Us  |  About Us  |  Advertise with Us  |  Sitemap  |  Terms & Conditions  |  Cookies  |  Privacy  |  Mobile Site  |  About this website design


Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.